Thank you for contacting me about support for people with motor neurone disease (MND). Please allow me to assure you that ensuring early diagnosis and support for those living with MND remains a key priority of the NHS.
With early diagnosis key to treating the symptoms of MND, I am glad that the National Institute for Health and Care Excellence (NICE) has published clear guidelines for clinicians on the assessment and management of MND. These set out the signs and symptoms of the disease, and recommend that patients suspected of having MND should be referred without delay. The Royal College of GPs and the MND Association have also worked together to produce a ‘Red Flag Tool’ which sets out key signs of MND to help GPs to identify suspected cases and ensure prompt referral.
I was extremely interested to read about the research undertaken by the University of Edinburgh which identified an issue with MND patients' nerve cells, suggesting that this damage could be repaired by improving the energy levels in mitochondria. While I understand that this research is still in early stages, it is a most welcome step forward, and I will certainly follow this closely.
I am encouraged that almost £288 million has been spent on research into neurological conditions, including MND, in the past decade through the publicly-funded National Institute for Health Research (NIHR). With the NIHR’s annual spending on neurological conditions up by more than £22 million in that period, I remain hopeful that this funding will discover new ways to improve the lives of those diagnosed with MND.
Over the past five years, the Department of Health and Social Care has spent over £9 million on MND research through the NIHR. Additionally, UK Research and Innovation, through the Medical Research Council, has spent £45 million on MND research over the past five years. This includes research which aims to increase understanding of the causes and genetic mechanisms of MND.
I have ensured that colleagues at HM Treasury are aware of your suggestions for the Spending Review taking place this year. While I am regrettably not in a position to pre-empt the conclusions of the review, I am assured by colleagues that they are aware of the policy suggestions you raised.
Thank you again for taking the time to contact me.
